The Issuance Window Is Wide Open — But It's Doing Two Things at Once

The first full trading week of July 2026 has produced one of the heaviest stretches of US equity issuance in years. SK hynix’s $28.1 billion Nasdaq listing dominates the calendar, but it is far from alone: Italian software group Bending Spoons raised $1.68 billion in its IPO and surged 40 percent on its first day, while Rivian, FuelCell Energy, Sable Offshore, and Abivax collectively tapped the secondary market for more than $3 billion in the same week. The issuance window is unquestionably open. What it means depends on which deals you are looking at.

The Anchor: SK hynix’s $28.1 Billion Nasdaq Listing

SK hynix set terms on Monday, July 6 for a US IPO of 177.9 million American Depositary Shares at $158.14 — the as-converted July 3 close of its shares on the Korea Exchange’s KOSPI market. At that price, the deal raises $28.1 billion and values the Icheon-based memory chipmaker at approximately $1.2 trillion{{cite:08d244d4b2d6}}.

The deal drew cornerstone indications from Baillie Gifford, Coatue Management, and Situational Awareness Partners totaling $7 billion, or 24.9 percent of the offering{{cite:08d244d4b2d6}}. Books closed early and the offering was oversubscribed ahead of pricing, signaling outsized investor appetite for AI-hardware exposure{{cite:a2cf3c9b0f10}}.

What makes this deal significant beyond its size — it is the largest-ever foreign IPO on a US exchange{{cite:a2cf3c9b0f10}} — is the strategic position it gives US investors. SK hynix ranked first or second globally in DRAM, high-bandwidth memory (HBM), and NAND flash by revenue in the first quarter of 2026{{cite:08d244d4b2d6}}. HBM is the specialized stacked memory inside every major AI accelerator, and SK hynix is the dominant supplier. The company booked $84.9 billion in revenue for the trailing twelve months ended March 31, 2026{{cite:08d244d4b2d6}}.

The underwriting syndicate is unusually broad: BofA Securities, Citi, Goldman Sachs, and J.P. Morgan lead, with Cantor Fitzgerald, Mizuho, Needham, RBC Capital Markets, Rosenblatt, Stifel, Wedbush, William Blair, WR Securities, and Nomura rounding out the book{{cite:08d244d4b2d6}}. The deal is expected to list on Nasdaq under the symbol SKHY.

The IPO That Proved the Window: Bending Spoons

Italian software company Bending Spoons priced its IPO at $29 per share on June 30, above the marketed range of $26 to $28, selling 57.97 million shares to raise $1.68 billion{{cite:fe655902c892}}. The company’s portion of the proceeds was approximately $954 million, with the remainder going to selling shareholders{{cite:fe655902c892}}.

The Milan-based firm, which acquires and operates digital businesses including Vimeo, WeTransfer, Evernote, AOL, and Brightcove, surged roughly 40 percent on its first day of trading on July 1{{cite:fe655902c892}}. That reception is notable because it came against a backdrop of SaaS-sector anxiety — investors have been wary that AI-native software could displace legacy applications{{cite:fe655902c892}}.

The Bending Spoons debut matters as a signal: it demonstrated that investors will pay up for a profitable, acquisition-driven software model even in a sector weighed down by AI-disruption fears. Pricing above range and a 40 percent first-day pop are the classic fingerprints of genuine IPO demand rather than a market simply tolerating new issuance.

The Other Side of the Window: Dilution at a Discount

The secondary market this week tells a less flattering story. Companies are raising capital, but several are doing so at steep discounts and paying for it in share-price terms.

Rivian (RIVN) priced 75 million shares at $15.50 on July 8, a significant discount to Monday’s closing price of $20.14{{cite:511d3b4b3c9d}}. Gross proceeds are approximately $1.16 billion, with a 30-day greenshoe option for 11.25 million additional shares that could lift the total to roughly $1.34 billion{{cite:511d3b4b3c9d}}. The stock fell 18 percent on the announcement{{cite:4d47a83a2ed7}}. Rivian plans to use the proceeds for general corporate purposes, including equity contributions tied to an amended Department of Energy loan agreement{{cite:511d3b4b3c9d}}.

The raise came days after Rivian reported stronger-than-expected Q2 deliveries of 12,194 vehicles, beating its prior outlook of 9,000 to 11,000, and raised its full-year delivery forecast to 65,000 to 70,000 vehicles from 62,000 to 67,000{{cite:511d3b4b3c9d}}. The company also pre-released Q2 revenue estimates of $1.55 billion to $1.65 billion, up from $1.30 billion a year earlier{{cite:511d3b4b3c9d}}. Even with that operational beat, investors focused on dilution. The offering is expected to close July 9.

FuelCell Energy (FCEL) upsized its offering from $200 million to 10,714,286 shares at $21.00 per share, raising approximately $225 million in gross proceeds{{cite:de3563e6643c}}. The stock plummeted 17 percent in after-hours trading on the announcement{{cite:de3563e6643c}} and was trading near $22.86, down roughly 12 percent intraday on July 8.

Sable Offshore (SOC) priced concurrent offerings on July 1: 32,467,533 shares of common stock at $3.08 per share and $300 million in 6.5 percent convertible senior notes due 2031{{cite:2dabe0f313cc}}. Underwriters fully exercised their options, bringing the final totals to 37,337,662 shares and $345 million in notes{{cite:2dabe0f313cc}}. The proceeds are earmarked for debt repayment{{cite:2dabe0f313cc}}.

Abivax (ABVX) closed a $920 million public offering on July 6, with underwriters fully exercising their option to purchase additional ADSs{{cite:b12d05edf8f0}}. The Paris-based clinical-stage biotech’s offering was among the largest life-sciences capital raises of the year.

Two Deals, Two Stories

The contrast between the IPO and secondary legs of this week’s issuance is worth sitting with. On the IPO side, SK hynix and Bending Spoons both priced at or above their reference points, drew cornerstone or oversubscribed demand, and traded up on debut. These are deals where investors are paying for exposure to a growth narrative — AI memory dominance, a profitable software roll-up — and the pricing reflects confidence in that narrative.

On the secondary side, Rivian, FuelCell Energy, and Sable Offshore are raising capital to fund operations, service debt, or meet government-loan obligations. The discounts are wide, the stock reactions are sharply negative, and the use of proceeds is defensive rather than expansionary. These are deals where the market is absorbing supply because it has to, not because it wants to.

One way to read this: the window is genuinely open for companies that offer a compelling growth story at a defensible valuation, and it is grudgingly open for companies that need cash to keep going. Both can be true simultaneously, and historically have been. The 2021 IPO boom had a similar dual character — high-quality names priced well while speculative or cash-burning companies raised on increasingly thin terms before the window eventually closed.

The Structural Backdrop

Scott Rubner, head of Equity and Equity Derivatives Strategy at Citadel Securities, published his 1H 2026 Market Structure & Flows review on June 30, arguing that “the defining story of 2026 has not been a single macro event, it has been the structural transformation of equity markets”{{cite:11ee14066e38}}. His framework centers on concentration, passive-flow dominance, and record retail participation as the forces reshaping how equities trade{{cite:11ee14066e38}}.

That structural context matters for interpreting the current issuance wave. If passive inflows and retail participation are mechanically supporting equity demand, then the system’s capacity to absorb new issuance is larger than it might appear from sentiment alone. But Rubner has also flagged flow fragility — in a May 18 note he warned that the market “may be vulnerable to a potential flow-of-funds unwind” after the S&P 500 added roughly $10 trillion in market cap from its March 30 low{{cite:11ee14066e38}}.

The rotation theme is also relevant. Equal-weight benchmarks have been outperforming, a sign that market leadership is broadening beyond the concentrated mega-cap names that drove the rally through May{{cite:11ee14066e38}}. A broadening rally is generally more hospitable to new issuance than a narrow one, because it implies capital is reaching a wider set of companies rather than being trapped at the top.

Meanwhile, the Federal Reserve Bank of New York and the University of Chicago Booth School’s Clark Center are hosting a joint workshop on July 9 titled “The Future of Market Liquidity and Functioning,” bringing together academics, industry experts, and current and former central bankers to discuss risks from innovations in payments and trading infrastructure{{cite:4191f5b1e948}}. The timing is coincidental but apt: the system is absorbing a record issuance week at the same moment its plumbing is under formal review.

The Week’s Issuance at a Glance

What to Watch Next

• SK hynix pricing and debut. The deal is expected to price the week of July 6 and begin trading shortly after. First-day performance will be the clearest read on whether AI-hardware appetite extends beyond the cornerstone cohort. Watch the opening print and the first week’s volume.

• Rivian’s post-offering trade. The stock was down roughly 4.4 percent in premarket on July 8 at $15.76, with the offering closing July 9{{cite:511d3b4b3c9d}}. Whether the stock stabilizes above the $14.50 support level or continues to drift will signal how the market is digesting the dilution.

• The NY Fed liquidity workshop on July 9. Any readouts or papers from the joint workshop on market functioning could inform the debate about whether current liquidity conditions are durable or fragile{{cite:4191f5b1e948}}.

• Geopolitical risk premium. Iran-related tensions resurfaced this week, with oil prices surging and risk appetite stumbling{{cite:4191f5b1e948}}. BofA’s technicals point to a corrective Q3 for the S&P 500{{cite:4191f5b1e948}}. A risk-off shift could narrow the issuance window quickly, particularly for the lower-quality secondaries.

• The IPO pipeline behind SK hynix. Tarsier Pharma is pricing this week at a $45 million deal size{{cite:f073d7a41927}}, and several SPACs are on the calendar{{cite:f073d7a41927}}. The depth and diversity of deals following the SK hynix mega-listing will show whether the window stays open for smaller names or narrows back to marquee issuers.

The base-rate reading is that issuance waves like this one — anchored by a single landmark deal, accompanied by a mix of quality IPOs and discount secondaries — tend to persist as long as liquidity conditions hold and volatility stays contained. The historical pattern also says they close abruptly when either condition breaks. The question for the second half of July is which force dominates: the structural demand that Rubner describes, or the geopolitical and flow-fragility risks that are visibly pressing at the edges.